Prelude Therapeutics【PRLD】銘柄情報

Prelude Therapeutics Inc (PRLD) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

4.49

( 9.25% )

買値

4.25

売値

4.59

出来高

315,437

3.97 日の範囲 4.52

0.75 52 週間の範囲 5.54

時価総額

445.307M

前日終値

4.11

始値

4.03

時刻

4.25

最終取引時間

財務取引量

US$ 1,372,195

VWAP

4.3501

平均取引量 (3 か月)

US$ 378,034

発行済株式数

99,177,495

配当利回り

PER

-3.99

1 株当たり利益 (EPS)

-0.99

歳入

16.72M

純利益

-77.8M

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis... Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

preludetx.com

本社

Wilmington, United States

設立

2026

Prelude Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker PRLD. The last closing price for Prelude Therapeutics was US$4.11. Over the last year, Prelude Therapeutics shares have traded in a share price range of US$ 0.75 to US$ 5.54.

Prelude Therapeutics currently has 99,177,495 shares in issue. The market capitalisation of Prelude Therapeutics is US$445.31 million. Prelude Therapeutics has a price to earnings ratio (PE ratio) of -3.99.

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD...

Form 8-K - Current report

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.44	10.8641975309	4.05	4.495	3.7418	227044	3.92229639	CS
4	0.16	3.69515011547	4.33	4.75	3.4	307055	4.07066554	CS
12	1.37	43.9102564103	3.12	5.54	2.83	384017	4.40166574	CS
26	2.875	178.018575851	1.615	5.54	1.6021	398429	3.34038985	CS
52	3.43	323.58490566	1.06	5.54	0.75	581940	2.69951601	CS
156	-0.93	-17.1586715867	5.42	6.8	0.6101	325408	2.56067825	CS
260	-26.71	-85.608974359	31.2	43.5499	0.6101	281265	6.29985297	CS